.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH02_Vildagliptin.Vildagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH02_Vildagliptin.Vildagliptin| name: | Vildagliptin |
| ATC code: | A10BH02 | route: | oral |
| n-compartments | 1 |
Vildagliptin is an oral antidiabetic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class, used in the management of type 2 diabetes mellitus to improve glycaemic control. It is approved for use in several countries worldwide.
Healthy adult volunteers, both male and female, after a single oral dose administration.
He, YL (2012). Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clinical pharmacokinetics 51(3) 147–162. DOI:10.2165/11598080-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22339447
He, YL, et al., & Howard, D (2007). The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clinical pharmacokinetics 46(9) 787–802. DOI:10.2165/00003088-200746090-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17713976
Tian, M, et al., & Yang, S (2025). Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects. Clinical pharmacology in drug development 14(2) 154–160. DOI:10.1002/cpdd.1482 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39444294